Literature DB >> 28542787

Understanding the reconstitution of the B-cell compartment in bone marrow and blood after treatment for B-cell precursor acute lymphoblastic leukaemia.

Prisca M J Theunissen1, Anouk van den Branden1, Alita Van Der Sluijs-Gelling2, Valerie De Haas2, Auke Beishuizen3, Jacques J M van Dongen1, Vincent H J Van Der Velden1.   

Abstract

A better understanding of the reconstitution of the B-cell compartment during and after treatment in B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) will help to assess the immunological status and needs of post-treatment BCP-ALL patients. Using 8-colour flow cytometry and proliferation-assays, we studied the composition and proliferation of both the B-cell precursor (BCP) population in the bone marrow (BM) and mature B-cell population in peripheral blood (PB) during and after BCP-ALL therapy. We found a normal BCP differentiation pattern and a delayed formation of classical CD38dim -naive mature B-cells, natural effector B-cells and memory B-cells in patients after chemotherapy. This B-cell differentiation/maturation pattern was strikingly similar to that during initial B-cell development in healthy infants. Tissue-resident plasma cells appeared to be partly protected from chemotherapy. Also, we found that the fast recovery of naive mature B-cell numbers after chemotherapy was the result of increased de novo BCP generation, rather than enhanced B-cell proliferation in BM or PB. These results indicate that post-treatment BCP-ALL patients will eventually re-establish a B-cell compartment with a composition and B-cell receptor repertoire similar to that in healthy children. Additionally, the formation of a new memory B-cell compartment suggests that revaccination might be beneficial after BCP-ALL therapy.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  B-cell precursors; B-cells; acute leukaemia; chemotherapy; reconstitution

Mesh:

Year:  2017        PMID: 28542787     DOI: 10.1111/bjh.14685

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  3 in total

1.  Early B cells repopulation in multiple sclerosis patients treated with rituximab is not predictive of a risk of relapse or clinical progression.

Authors:  Guillaume Dorcet; Hugo Migné; Damien Biotti; Chloé Bost; Fleur Lerebours; Jonathan Ciron; Emmanuel Treiner
Journal:  J Neurol       Date:  2022-06-02       Impact factor: 6.682

2.  Quality Assessment of a Large Multi-Center Flow Cytometric Dataset of Acute Myeloid Leukemia Patients-A EuroFlow Study.

Authors:  Anne E Bras; Sergio Matarraz; Stefan Nierkens; Paula Fernández; Jan Philippé; Carmen-Mariana Aanei; Fabiana Vieira de Mello; Leire Burgos; Alita J van der Sluijs-Gelling; Georgiana Emilia Grigore; Jacques J M van Dongen; Alberto Orfao; Vincent H J van der Velden
Journal:  Cancers (Basel)       Date:  2022-04-15       Impact factor: 6.575

3.  VS38c and CD38-Multiepitope Antibodies Provide Highly Comparable Minimal Residual Disease Data in Patients With Multiple Myeloma.

Authors:  Annemiek Broijl; Augustinus C M de Jong; Mark van Duin; Pieter Sonneveld; Jesper Kühnau; Vincent H J van der Velden
Journal:  Am J Clin Pathol       Date:  2022-04-01       Impact factor: 2.493

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.